

2019 HEDIS® MEASURE: AVOIDANCE OF ANTIBIOTIC TREATMENT IN ADULTS WITH ACUTE BRONCHITIS (AAB)

Gold Coast Health Plan's goal is to help its providers gain compliance with their annual Healthcare Effectiveness Data and Information Set (HEDIS®) scores by providing guidance and resources. This tip sheet will provide the key components to the HEDIS® measure, "Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)."

Measure Description: Members ages 18 to 64 with a diagnosis of acute bronchitis. This measure requires that every adult who received the diagnosis DOES NOT receive an antibiotic unless they have a co-morbid condition and/or a competing diagnosis that requires the use of a prescription antibiotic.

This measure is reported as an inverted rate, which means that a higher rate signifies better performance in the appropriate treatment of members with uncomplicated bronchitis. This measure also relies on administrative claims information to identify the eligible population diagnosed during the measurement year with uncomplicated acute bronchitis (without evidence of bacterial infection and/or co-morbidity) and who were inappropriately prescribed an antibiotic.

Codes used to identify the patient with acute bronchitis

Description	ICD-10-CM Diagnosis
Acute bronchitis	J20.3 – J20.9

Co-morbid conditions and competing diagnoses that exclude members from the AAB measure

Codes used to identify co-morbid conditions

Description	ICD-10-CM Diagnosis
Bronchiectasis	J47.0 – J47.9
COPD	J44.0 – J44.9
Chronic bronchitis	J41.0 – J42
Cystic fibrosis	E84.0 – E84.9
Sickle Cell Disease with Acute Chest	D57.01, D57.211, D57.411, D57.811
Emphysema	J43.0 – J43.9
HIV HIV Type 2 HIV asymptomatic	B20 B97.35 Z21
Malignant neoplasms	C00.0- C96.Z
Other diseases of the respiratory system	B44.81, J22, J80 – J96.92, J99, M30.1, M32.13, M33.01, M33.11, M33.21, M33.91, M34.81, M35.02
Pneumoconiosis and other lung disease due to external agents	J60 – J68.3, J68.9, J70 – J70.9
Tuberculosis	A15 – A19.9, O98.011 – O98.03
Disorders of the Immune System	D80.0 – D80.9, D81.0 – D81.2, D81.4, D81.6 – D81.7, D81.89, D81.9, D82.0 – D82.4, D82.8 – D82.9, DA83.0 – D82.9, D84.0 – D84.9, D89.3, D89.810 – D89.813, D89.82 – D89.9

Codes used to identify competing diagnoses identified 30 days prior and seven days after the diagnosis of acute bronchitis

Description	ICD-10-CM Diagnosis
Acute Upper Respiratory Infections	J02.0 – J02.9, J03.00 – J03.91
Infectious and Parasitic Diseases	A00.0 – A09, A37.00 – A37.91, A44.0 – A44.9, A49.9, A50.01 – A59.9, A63.0 – A64, A69.0 – A69.9, B60.0 – B64, B78.1, B96.89
Metabolic Disorder	E83.2
Disorders of the Ear	H66.01 – H67.9, H70.001 – H70.93, H95.00 – H95.89
Disorders of the Respiratory System	J01.00 – J03.91, J04.10, J04.11, J04.2, J05.0 – J05.11, J13 – J18.9, J20.0 – J20.2, J32.0 – J32.9, J35.01 – J39.9
Digestive System Diseases	K12.2
Integumentary System Diseases	L01.00 – L01.1, L03.011 – L04.9, L08.1 – L08.9, L88, L92.8, L98.0, L98.3
Musculoskeletal System and Connective Tissue Disease	M46.20 – M46.39, M89.00 – M89.9, M90.80 – M90.89
Genitourinary Diseases	N10 – N12, N13.0, N13.6, N15.1, N16, N28.84 – N28.86, N30.00 – N30.91, N39.0, N41.0 – N41.9, N70.01 – N77.1
Health Hazards Related to Communicable Diseases	Z20.2, Z22.4

Best Practices:

- ▶ Set appropriate expectations for duration of symptoms and provide specific directions to the members to achieve symptomatic relief.
- ▶ Educate members about the risks of inappropriate antibiotic use.
- ▶ Caution patients regarding symptoms indicating more severe disease.
- ▶ Use the most accurate codes to reflect the correct diagnosis
- ▶ Submit your claim for all diagnoses, including all co-morbid and competing conditions so the member can be excluded from this measure, where applicable.
- ▶ Do not exclude asthma (J45), diabetes (E08 – E13), tobacco use, fever or wheezing, as they are not co-morbid or competing conditions.

*More information on patient communication and provider education can be obtained from the Centers for Disease Control and Prevention's [Be Antibiotics Aware](#) campaign.

For additional information on specific HEDIS® measures, please visit the websites for the [National Committee for Quality Assurance \(NCQA\)](#) or the [Agency for Healthcare Research and Quality \(AHRQ\)](#).

Effective January 1, 2014, NCQA replaced the coding tables with “value sets” which contain all applicable codes that can be used to identify a specific service or condition included in any measure. Detailed information on the data sets and technical specifications can be found [here](#).

GCHP does not intend this information to be medical advice, but a tool to assist in compliance with the HEDIS® measures.